FIELD: medicine.
SUBSTANCE: invention relates to a method of producing noribogaine. Method includes:
a) converting voacangine into 12-hydroxyibogamine-18-carboxylic acid ester, wherein indole nitrogen is optionally protected by an amino protecting group; b) optionally isolating 12-hydroxyibogamine-18-carboxylic acid ester and/or its amino-protective derivative; c) converting 12-hydroxyibogamine-18-carboxylic acid ester and/or its amino-protective derivative obtained at step a) or b), into noribogaine; and d) isolating obtained noribogaine. Also disclosed are versions of method and compounds containing salt.
EFFECT: disclosed method of producing noribogaine from voacangine enables effective and reliable minimisation of ibogamine impurities.
13 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NORIBOGAINE COMPOSITIONS | 2011 |
|
RU2586296C2 |
| DERIVATIVES OF UREA, METHOD OF THEIR SYNTHESIS (VARIANTS) AND MEDICINAL AGENT | 1998 |
|
RU2198883C2 |
| NEW METHOD AND NEW INTERMEDIATE COMPOUNDS | 2016 |
|
RU2769445C2 |
| 6-OXO-AZEPINOINDOLE COMPOUNDS AND THEIR PHYSIOLOGICALLY TOLERANTABLE ACID SALTS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS OF THEIR SYNTHESIS | 1992 |
|
RU2078765C1 |
| DERIVATIVES OF CYCLOPEPTIDES AS ADHESION INHIBITORS | 1998 |
|
RU2200166C2 |
| 2-(2-AMINO-1,6-DIHYDRO-6-OXOPURIN-9-YL)METOXY-3-HYDROXY- 1-PROPANYL-L-VALINATE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD OF PREPARING THEREOF, PHARMACEUTICAL COMPOSITION AND HYDROXY AND/OR AMINO PROTECTED 2-(2- AMINO-1,6-DIHYDRO-6-OXOPYRIN-9-YL) METHOXY-3-HYDROXY-1- PROPANYL-L-VALINATE | 1995 |
|
RU2133749C1 |
| CYCLOPEPTIDE DERIVATIVES | 1997 |
|
RU2202557C2 |
| CYCLIC AZAPEPTIDES WITH ANGIOGENIC EFFECT | 1998 |
|
RU2188205C2 |
| METHODS OF PRODUCING (3R, 3aS, 6aR) HEXAHYDROFURO[2,3-b]FURAN-3-OL | 2005 |
|
RU2421458C2 |
| BIARYLOXYMETHYLARENE CARBOXYLIC ACIDS | 2004 |
|
RU2373187C2 |
